Monopar Therapeutics, Inc. Announces Acquisition of GPX-150, a Broad Spectrum Phase II Cancer Drug Candidate, Closing on $9.7M in Financing, and Filing of Form 10 Registration Statement Nov 14, 2017
Monopar Therapeutics Announces Partnership With Cancer Research UK And Cancer Research Technology To Develop New Oncology Compound Jul 9, 2015
Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award Jul 7, 2015
